Trial Profile
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2016
Price :
$35
*
At a glance
- Drugs QS 21 (Primary) ; Vanutide cridificar (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Mar 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov (extension study: NCT00960531).